Savara’s (SVRA) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reissued their market outperform rating on shares of Savara (NASDAQ:SVRA) in a research report released on Thursday,Benzinga reports. The brokerage currently has a $9.00 price objective on the stock.

Other equities analysts have also issued reports about the company. Evercore ISI reiterated an “in-line” rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. HC Wainwright dropped their price target on Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.86.

Savara Price Performance

Shares of Savara stock opened at $3.23 on Thursday. Savara has a 12-month low of $2.82 and a 12-month high of $5.70. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock has a 50 day moving average price of $3.47 and a two-hundred day moving average price of $3.98. The stock has a market capitalization of $554.33 million, a P/E ratio of -7.51 and a beta of 0.92.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). Equities analysts expect that Savara will post -0.45 earnings per share for the current year.

Insider Activity at Savara

In other news, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the transaction, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This trade represents a 3.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph S. Mccracken bought 20,000 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the purchase, the director now owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 5.13% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its holdings in shares of Savara by 22.9% in the 3rd quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock worth $36,566,000 after buying an additional 1,608,522 shares in the last quarter. Frazier Life Sciences Management L.P. grew its position in Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after acquiring an additional 4,157,385 shares during the period. Vestal Point Capital LP raised its stake in Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock worth $34,302,000 after acquiring an additional 1,600,000 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of Savara by 17.5% during the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock valued at $28,547,000 after acquiring an additional 1,001,296 shares during the period. Finally, Nantahala Capital Management LLC boosted its stake in shares of Savara by 198.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after purchasing an additional 3,443,541 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.